Navigation Links
Genaera Corporation Announces 2007 Financial Results
Date:3/31/2008

s primarily due to an increase in clinical, manufacturing, research and personnel costs related to the trodusquemine (MSI-1436) program for the treatment of type 2 diabetes and obesity and an increase in stock-based compensation related to stock options granted throughout the year. This increase was partially offset by a decrease in indirect personnel costs associated with reductions in force in 2007.

Genaera's general and administrative expenses for the year and quarter ended December 31, 2007 were $6.8 million and $2.5 million, respectively, compared to $6.0 million and $1.5 million, respectively, for the same periods in 2006. The increase in general and administrative expenses for the year ended December 31, 2007 as compared to the same period in 2006 was due principally to an increase in legal fees associated with the Company's 2007 strategic review and realignment costs associated with reductions in force in 2007. The increase in general and administrative expenses for the quarter ended December 31, 2007 as compared to the same period in 2006 was due principally to an increase in stock-based compensation related to stock options granted throughout the year.

The Company's cash, cash equivalents and short-term investment balance was $20.9 million at December 31, 2007.

"In early 2007, we conducted a comprehensive review of our development portfolio to focus on Genaera's product assets with the greatest commercial potential," stated Jack Armstrong, President and CEO. "As a result, we undertook a restructuring and strategic refocusing initiative to concentrate on two core programs, MSI-1436 for the treatment of type 2 diabetes and obesity being developed internally, and MEDI-528 for the treatment of asthma being developed by our partner, MedImmune, Inc. Both programs advanced in the clinic in 2007. The first phase 1 trial of MSI-1436 in healthy, obese and overweight volunteers was completed in October 2007 and a second phase 1 study in obese typ
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
9. BioElectronics Corporation Announces Singapore and Malaysia Sales
10. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
11. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... Report" report to their offering. This ... (SOFCs) in US$ Thousands. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , and Rest ... period 2012 through 2020. Market data and analytics are derived ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... M plus potential annual revenue to ProMetic derived from first ... hyperimmune product - Kedrion ... technology in Kedrion,s ... process, MONTREAL, Feb. 26 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,("ProMetic") (TSX:PLI) announced today ...
... pathogen detection capabilities for air samples using an advanced ... ... Systems Inc.,(MFSI) today announced that it has signed agreements with ... Applera Corporation,business, and Hamilton Sundstrand, a United Technologies (NYSE: ...
... up from $42 ... product sales expected with delivery of ABthrax(TM) to ... - First Albuferon(R) Phase 3 data expected late 2008 -, - Enrollment completed in randomized Phase 2 ... myeloma -, ...
Cached Biology Technology:ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 2ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 4Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies' Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System 2Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies' Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System 3Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 2Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 3Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 4Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 5Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 6Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 7Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 8Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 9Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 10Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 11
(Date:8/20/2014)... Arizona State University, the Wellcome Trust Sanger Institute and ... isolated Mycobacterium pinnipedii from skeletons found in ... pathogen is a relative of the TB bacterium that ... today. These researchers assume that seals carried the pathogens ... sea lions was unexpected" comments Sebastien Gagneux, from the ...
(Date:8/20/2014)... Calif., August 19, 2014 -- Bay Area Lyme Foundation, ... and simple to cure, applauds new research published in ... Ticks and Tick-borne Diseases . The findings ... California are active throughout the year, making the threat ... researchers at California Department of Public Health (CDPH) Vector-borne ...
(Date:8/20/2014)... have suffered concussions ready to return to action? A ... school athletes who head back on the field with ... in their abilities to simultaneously walk and do simple ... in their balance and/or altered walking speed, was found ... had returned to activity in less than a month. ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... research from Rice University, Baylor College of Medicine (BCM) and ... of flow in the small blood vessels of the heart ... and form dangerous blood clots. The scientists were surprised to ... shape for up to five hours before returning to their ...
... Department of Energy,s National Renewable Energy Laboratory (NREL) eases and ... industry: determining cell wall chemistry to find plants with ideal ... thoroughly analyze hundreds of biomass samples a day and give ... pursuing. Analysis of a sample that previously took two weeks ...
... VA As the Colorado River winds through the Colorado ... of sediment. This sediment which once left the river,s ... Colorado "the reddish river" is a vital component to ... of the Hoover and Glen Canyon dams, which trap the ...
Cached Biology News:Stressed proteins can cause blood clots for hours 2Stressed proteins can cause blood clots for hours 3Biomass analysis tool is faster, more precise 2Biomass analysis tool is faster, more precise 3Biomass analysis tool is faster, more precise 4Biomass analysis tool is faster, more precise 5
... Rat Antibody to Human CD66 ... is expressed by human neutrophils and ... carcinoma. Clone YTH71.3 reacts with transfectants ... are CEA subfamily members(2). ...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Request Info...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Biology Products: